Exact Sciences (EXAS +9.6%) is up on average volume in apparent response to data from colorectal cancer (CRC) biopsy samples generated by privately held Freenome. William Blair’s Brian Weinstein says the results, as they relate to CRC screening, do not present a threat to Cologuard. BTIG’s Amanda Murphy agrees, adding that Freenome’s approach comparing results across trials is “flawed.”
The data are being presented at the ASCO GI Cancers Symposium in San Francisco.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.